Rybelsus 7 mg tablets
Sponsors
Rigshospitalet, Universitair Medisch Centrum Groningen, Novo Nordisk A/S, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, AstraZeneca AB
Conditions
Chronic Kidney DiseaseCoronary Artery DiseaseCoronary AtherosclerosisCoronary Heart DiseaseDiabetes type 2GlaucomaHyperglycaemia after renal transplantationMild cognitive impairment (MCI) or mild dementia
Phase 2
Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation
WithdrawnCTIS2023-504159-29-00
Target: 104Updated: 2023-07-17
Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation
RecruitingCTIS2023-504159-29-01
Start: 2024-09-03Target: 104Updated: 2025-11-03
FINESSE; Optimization of albuminuria lowering therapies to individual patients with CKD using FINErenone and SEmaglutide (FINESSE-CKD)
RecruitingCTIS2023-506434-69-00
Start: 2025-02-11Target: 36Updated: 2024-08-28
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax)
RecruitingCTIS2024-513416-98-00
Start: 2023-01-23Target: 90Updated: 2025-11-25
Effects of GLP-1 analogue in multiple sclerosis
Not yet recruitingCTIS2024-519235-42-00
Target: 1Updated: 2024-11-07
A Phase Ilb, Randomized, Double-blind, Placebo controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
CompletedCTIS2024-512562-34-00
Start: 2025-02-24End: 2025-12-17Target: 118Updated: 2025-11-19
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus
RecruitingCTIS2024-520322-11-00
Start: 2025-09-29Target: 74Updated: 2025-09-08
Phase 3
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
Active, not recruitingCTIS2023-506918-45-00
Start: 2021-05-17Target: 798Updated: 2025-11-24
PIONEER TEENS
Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes.
CompletedCTIS2023-506923-27-00
Start: 2020-10-30End: 2025-12-17Target: 20Updated: 2025-10-27
Phase 4
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with coronary artery disease and preDiabetES. A randomised clinical trial (CASCADES)
RecruitingCTIS2023-508525-27-00
Start: 2025-07-10Target: 300Updated: 2025-08-27
Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON)
RecruitingCTIS2024-518510-87-00
Start: 2025-04-10Target: 126Updated: 2024-11-15